Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.39 |
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528622 | 0.91 | CDK1 (0.39) | CDK1KDRBTKAXLMAPK1 | |
| SCHEMBL6888385 | 0.87 | CDK1 (0.53) | CDK1KDRBTKMAPK1 | |
| SCHEMBL6512138 | 0.85 | CDK1 (0.37) | CDK1KDRBTKCDK2CCNT1 | |
| SCHEMBL6510344 | 0.81 | EGFR (0.41) | CDK1KDRBTKAXLMAPK1 | |
| SCHEMBL6532726 | 0.80 | CDK1 (0.46) | CDK1KDRAXL | |
| SCHEMBL6528626 | 0.79 | PTK2 (0.36) | BTKMAPK1 | |
| SCHEMBL6517883 | 0.75 | CDK1 (0.65) | CDK1KDR | |
| SCHEMBL6519455 | 0.71 | CDK1 (0.68) | CDK1KDRBTK | |
| SCHEMBL6888387 | 0.70 | CDK1 (0.47) | CDK1KDRBTKMAPK1 | |
| SCHEMBL6511549 | 0.70 | CDK1 (0.49) | CDK1KDRBTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | CDK1 435/4885KDR 8/4885BTK 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.